Figure 4.

Effect of post-treatment on joint swelling and lameness throughout the study period. Right knee joints of all sensitised rats were injected with antigen on Day 0. Treatment was commenced two days following arthritis induction. Representative reduction in knee width (A) and gait score (B) throughout the trial period (Days 0 to 14) was attained by calculating the average area under the curve of data displayed in Figure 3. sPLA2I treatment at 5 or 10 mg/kg achieved a significant reduction in both joint swelling (P < 0.001 and P < 0.01 respectively) and lameness (P < 0.01 and P < 0.05 respectively) over the trial period (A, B). Infliximab significantly reduced joint swelling (P < 0.05) without effecting lameness (A), and prednisolone significantly reduced lameness (P < 0.05) without effecting swelling (B). Each column represents mean ± SEM.

Coulthard et al. Arthritis Research & Therapy 2011 13:R42   doi:10.1186/ar3278
Download authors' original image